152 related articles for article (PubMed ID: 16998285)
1. [PIVKA-II as a serological marker of hepatocellular carcinoma].
Jeong SH
Korean J Hepatol; 2006 Sep; 12(3):315-7. PubMed ID: 16998285
[No Abstract] [Full Text] [Related]
2. [PIVKA-II high-sensitivity PIVKA-II].
Fujiyama S
Nihon Rinsho; 2001 Oct; 59 Suppl 6():349-55. PubMed ID: 11761970
[No Abstract] [Full Text] [Related]
3. [Molecular markers for early diagnosis of hepatocellular carcinoma].
Yao DF
Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):492. PubMed ID: 15329213
[No Abstract] [Full Text] [Related]
4. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
5. [Tumor markers for hepatocellular carcinoma].
Fujiyama S; Tanaka M; Maeda S; Ashihara H; Hirata R
Gan To Kagaku Ryoho; 2001 May; 28(5):723-32. PubMed ID: 11383225
[TBL] [Abstract][Full Text] [Related]
6. [Clinical signification and evaluation of PIVKA-II in hepatocellular carcinoma].
Matsushima A; Enomoto M; Yokoo Y; Arai M; Kobayashi T; Okuno F; Hirano Y; Sujita K; Eto S; Takagi T
Rinsho Byori; 1989 Jun; 37(6):683-6. PubMed ID: 2477568
[No Abstract] [Full Text] [Related]
7. [Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma].
Yoon YJ; Han KH; Kim C; Chon CY; Moon YM; Han CH; Choi HJ; Kim YS; Han JY; Kim HS
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):465-71. PubMed ID: 12506251
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody].
Ohtani M; Ido K; Kawamoto C; Kimura K
Rinsho Byori; 1989 Apr; 37(4):405-9. PubMed ID: 2545953
[No Abstract] [Full Text] [Related]
9. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
10. [Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis].
Aoyagi Y; Yanagi M; Asakura H
Nihon Naika Gakkai Zasshi; 1995 Dec; 84(12):2003-7. PubMed ID: 8586921
[No Abstract] [Full Text] [Related]
11. [Evaluation of serum PIVKA-II by Lumipulse PrestoII assay].
Hiramatsu K; Tanaka Y; Takagi K; Kani S; Goto T; Takasaka Y; Matsuura K; Sugauchi F; Moriyama K; Murakami H; Kitajima S; Mizokami M
Rinsho Byori; 2009 Mar; 57(3):200-5. PubMed ID: 19363989
[TBL] [Abstract][Full Text] [Related]
12. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers.
Iizuka N; Oka M; Sakaida I; Moribe T; Miura T; Kimura N; Tamatsukuri S; Ishitsuka H; Uchida K; Terai S; Yamashita S; Okita K; Sakata K; Karino Y; Toyota J; Ando E; Ide T; Sata M; Tsunedomi R; Tsutsui M; Iida M; Tokuhisa Y; Sakamoto K; Tamesa T; Fujita Y; Hamamoto Y
Clin Chim Acta; 2011 Jan; 412(1-2):152-8. PubMed ID: 20883676
[TBL] [Abstract][Full Text] [Related]
13. Des-gamma-carboxy prothrombin (PIVKA-II)-producing mediastinal embryonal carcinoma with features of hepatoid differentiation.
Hasegawa Y; Tomita K; Hashimoto K; Shigeoka Y; Watanabe M; Yamasaki A; Shimizu E
Anticancer Res; 2005; 25(6C):4569-71. PubMed ID: 16334143
[TBL] [Abstract][Full Text] [Related]
14. [Development of highly sensitive assay for detection of low serum level of PIVKA-II and its clinical usefulness].
Sakizono K; Oita T; Kuroda M; Kasakura S
Rinsho Byori; 1996 Sep; 44(9):871-6. PubMed ID: 8911073
[TBL] [Abstract][Full Text] [Related]
15. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
Sakizono K; Oita T; Shibata Y; Tamura A; Kasakura S
Rinsho Byori; 1998 Sep; 46(9):936-41. PubMed ID: 9800480
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma.
Ajisaka H; Shimizu K; Miwa K
J Surg Oncol; 2003 Oct; 84(2):89-93. PubMed ID: 14502782
[TBL] [Abstract][Full Text] [Related]
17. [False positive serum des-gamma-carboxy prothrombin after resection of hepatocellular carcinoma].
Hiramatsu K; Tanaka Y; Takagi K; Iida T; Takasaka Y; Mizokami M
Rinsho Byori; 2007 Apr; 55(4):330-7. PubMed ID: 17511263
[TBL] [Abstract][Full Text] [Related]
18. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.
Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Nagai T; Minami Y; Ueshima K
Oncology; 2008; 75 Suppl 1():91-8. PubMed ID: 19092277
[TBL] [Abstract][Full Text] [Related]
19. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
20. Serological markers of liver cancer.
Yuen MF; Lai CL
Best Pract Res Clin Gastroenterol; 2005 Feb; 19(1):91-9. PubMed ID: 15757806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
